GlassScriptPhysician profile
Nirmal Kumar Kumaradas Antonio
NPI 1518186451
$3,693.70
in general payments reported to CMS, 2019-2025
38 companies · $549 in 2025
The $549 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $330 · 2020: $755 · 2021: $595 · 2022: $742 · 2023: $587 · 2024: $134 · 2025: $549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,177 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,176.79 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $451.91 | 2019-2023 | Shingrix |
| Merck Sharp & Dohme LLC | $428.29 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Bayer Healthcare Pharmaceuticals INC. | $346.51 | 2022-2025 | |
| Abbvie INC. | $270.01 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $259.67 | 2019-2024 | Lokelma, Airsupra, Farxiga |
| Amgen INC. | $177.78 | 2020-2023 | Repatha, Otezla |
| Novo Nordisk INC | $164.33 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $159.10 | 2020-2025 | Jardiance |
| Amarin Pharma, INC. | $147.31 | 2019-2022 | |
| Astellas Pharma US INC | $143.01 | 2023-2025 | Veozah |
| Allergan, INC. | $140.95 | 2020 | |
| Pfizer INC. | $116.41 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $99.05 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $80.47 | 2020-2021 | |
| Insulet Corporation | $61.17 | 2025 | Omnipod |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nirmal Kumar Kumaradas Antonio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.